Acrongenomics, Inc. is a publicly traded company under the symbol (AGNM) that focuses on developing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, customer-orientated applications. The company has its international headquarters in Geneva, Switzerland.

As the global population escalates every year, medical providers are constantly seeking technologically advanced products and processes from diagnostics to treatment to monitoring patient diseases. We anticipate the technological changes we will inevitably encounter and strive to play an influential role in advancing medical technologies that will undoubtedly benefit the medical community around the world.

Acrongenomics is confident of its ability to satisfy its shareholders and employees by constantly evaluating its business strategy by collaborating with well-established research institutions and investing in innovative scientific projects, converting them into commercial opportunities.